Abstract

The present invention relates to novel compounds having an effect as i.a. galectin inhibitors, to the use of said compounds as a medicament as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal, where in said galectin is preferably a galectin-3. The novel compounds are defined by the general formula: (I)

IPC Classes  ?

• C07H 15/22 - Cyclohexane rings, substituted by nitrogen atoms
• A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
• A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• C07H 19/056 - Triazole or tetrazole radicals
• C07H 5/06 - Aminosugars

Abstract

Immunostimulatory methods and systems for treating or preventing atheros- clerosis and/or a condition associated thereto in an individual.

IPC Classes  ?

• C07K 14/725 - T-cell receptors
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• C07K 14/775 - Apolipopeptides
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention relates to a process for the manufacture of a zirconium oxide prosthesis, said zirconium oxide being stabilized, which proces comprises the following steps: a) compacting a zirconium oxide powder at a pressure of at least 45 MPa to an object of a desired form, b) impacting an etchable medium into the surface, c) optionally working the object to a final shape, d) sintering the body at a temperature of above 117O0C to transfer zirconium oxide into a tetragonal crystalline structure, and e) etching the etchable medium using hydrofluoric acid to remove the medium and impart a micromechanical retention surface. The invention also relates to a prosthesis prepared by this process.

IPC Classes  ?

• A61C 13/09 - Multilayer teeth
• A61C 8/00 - Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereonDental implantsImplanting tools
• C04B 35/486 - Fine ceramics
• C04B 41/91 - After-treatment of mortars, concrete, artificial stone or ceramicsTreatment of natural stone of only ceramics involving the removal of part of the materials of the treated articles, e.g. etching
• C04B 41/45 - Coating or impregnating
• C04B 41/53 - After-treatment of mortars, concrete, artificial stone or ceramicsTreatment of natural stone involving the removal of part of the materials of the treated article

Abstract

The present invention relates to complete oxidized LDL specific IgG fused or conjugated with at least one of the proteins of the group IL-10, TIMPs, and TGFβs to be used in a medicine, the use thereof for treatment of atherosclerosis and prevention of clinical events in patients with atherosclerosis, pharmaceutical compositions containing the same, as well as method for treatment of atherosclerosis and prevention of clinical events in patients with atherosclerosis.

IPC Classes  ?

• C07K 19/00 - Hybrid peptides
• A61K 38/18 - Growth factorsGrowth regulators
• A61K 38/20 - Interleukins
• A61K 38/55 - Protease inhibitors
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 14/495 - Transforming growth factor [TGF]
• C07K 14/54 - Interleukins [IL]
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

The present invention relates to an implantable barrier disc to be used in the negative pressure treatment of wounds, such as sternotomy wounds, which consists of an essentially rigid material that withstands a pressure of - 20 mmHg without being undergoing major deformation and which has at least an impermeable part which is to be placed over an organ or a vital tissue to protect it from being exposed to the wound opening and from being exposed to the negative pressure.

IPC Classes  ?

• A61B 17/00 - Surgical instruments, devices or methods
• A61F 13/14 - Bandages or dressingsAbsorbent pads specially adapted for the breast or abdomen
• A61M 27/00 - Drainage appliances for wounds, or the like

Abstract

The present invention relates to novel synthesis routes for preparation of thiodigalactosides of the general formula (12). The method comprises the use of a 3-azido-galactosyl thiouronium salt derivative, which is activated to the corresponding thiol in situ, which in turn is directly reacted with a 3-azido-galactosyl bromide resulting in the 3,3'-di-azido-thio-di-galactoside before the thiol has a chance to reduce the azido 10 group. Hence, in situ formation of the 3-azido-galactosyl thiol from the thiouronium salt is essential in the synthesis procedure, because any other method that generate the thiol separately results in extensive unwanted azide reduction.

IPC Classes  ?

• C07H 1/00 - Processes for the preparation of sugar derivatives
• C07H 15/04 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical
• C07H 15/18 - Acyclic radicals, substituted by carbocyclic rings
• C07H 19/056 - Triazole or tetrazole radicals
• C07H 3/04 - Disaccharides
• C07H 5/06 - Aminosugars
• C07H 5/10 - Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium, or tellurium to sulfur

Abstract

The present invention relates to novel GABAA/BzR ligands of the general formulas (I), (II) and (III) wherein R1 is selected from the group consisting of hydrogen, halogen, haloalkyl having 1-2 carbon atoms, alkoxy having 1 to 3 carbon atoms in the alkyl chain, alkyl having 1 to 3 carbon atoms, and nitro, and R2 is selected from the group consisting of hydrogen, halogen and alkyl having 1 to 2 carbon atoms, as well as the use of these compounds for treating anxiolytic, anticonvulsant, sedative- hypnotic and myorelaxant conditions as well as anxiogenic, somnolytic and convulsant conditions in mammals including pharmaceutical compositions comprising the same

IPC Classes  ?

• C07D 513/04 - Ortho-condensed systems
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/08 - AntiepilepticsAnticonvulsants
• A61P 25/20 - HypnoticsSedatives
• A61P 25/22 - Anxiolytics
• C07D 498/04 - Ortho-condensed systems
• A61K 31/4355 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
• A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine

Abstract

the resent invention relates to novel compounds of the general formula (I) having anxiolytic, anticonvulsant, sedative-hypnotic and myorelaxant conditions as well as anxiogenic, somnolytic and convulsant conditions in mammals, including humans, as GABAA receptor modulator.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 25/20 - HypnoticsSedatives
• A61P 25/22 - Anxiolytics

Abstract

The present invention relates to an aptamer or an active fragment thereof raised against the semi-conserved duffy binding ligand domain 1α, DBL1α, region of the Plasmodium falciparum erythrocyte membrane protein 1, PfEMPI, which aptamer has an effect against malaria, in particular severe cerebral malaria.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• A61P 33/06 - Antimalarials
• C07K 14/445 - Plasmodium
• C12R 1/90 - Protozoa

Abstract

An apparatus (1) for making chips (2), comprises a source (4) of heat, and a conveyer belt (6) arranged such that, when in use, chips (2) are held between the belt (6) and the heat source (4) at least a part of the path of the belt (6), and wherein the belt (6) is steam permeable. Also, a method for making chips (2) comprising feeding sliced mono layered food between a steam permeable conveyer belt (6) and a heat source (4) and guiding steam from the food through the steam permeable belt (6).

IPC Classes  ?

• A23L 1/214 - of tuberous or like starch containing root crops
• F26B 3/24 - Drying solid materials or objects by processes involving the application of heat by conduction, i.e. the heat is conveyed from the heat source, e.g. gas flame, to the materials or objects to be dried by direct contact the heat source and the materials or objects to be dried being in relative motion, e.g. of vibration the movement being rotation
• A21B 1/48 - Bakers' ovens characterised by the baking surfaces moving during the baking with surfaces in the form of an endless band
• A47J 37/04 - Roasting apparatus with movably-mounted food supports or with movable heating implementsSpits
• H05B 6/80 - Apparatus for specific applications

Abstract

The present invention relates to a method for monitoring the risk of obtaining a cancer disease, in particular colon cancer, lymphoma, prostate cancer, malignant skin non- melanoma, malignant melanoma, leukaemia, bladder cancer, breast cancer, in particular malignant melanoma, leukaemia, bladder cancer, and breast cancer, whereby the frequencies of genetic variants of Bloom syndrome protein, and topoisomerase IIIa (TOP3A) and RECQ-mediated genome instability 1 protein (RMI1) are determined, and when a significant increased presence of certain alleles and/or combinations of alleles ispresence, the risk is significant.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61P 35/00 - Antineoplastic agents
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

An apparatus (1) for making food chips (2), comprises a source (4) of heat, and a conveyer belt (6) arranged such that, when in use, food chips (2) are held between the belt (6) and the heat source (4) at least a part of the path of the belt (6), and wherein the belt (6) is steam permeable. Also, a method for making food chips (2) comprising feeding sliced mono layered food between a steam permeable conveyer belt (6) and a heat source (4) and guiding steam from the food through the steam permeable belt (6).

IPC Classes  ?

• A23L 1/214 - of tuberous or like starch containing root crops
• F26B 3/24 - Drying solid materials or objects by processes involving the application of heat by conduction, i.e. the heat is conveyed from the heat source, e.g. gas flame, to the materials or objects to be dried by direct contact the heat source and the materials or objects to be dried being in relative motion, e.g. of vibration the movement being rotation

Abstract

The present invention relates to siRNAs with sense (passenger) strands deviating from that of a target gene by having introduced metallated bases in the sense (passenger) strand, as well as a method for locally decreasing the melting temperature and concomitant structural change of siRNA, and a method for targeting mRNA regions.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• A61P 35/04 - Antineoplastic agents specific for metastasis

Abstract

The present invention relates to the use of oxytocin in the preparation of a pharmaceutical composition for improving gastric emptying in individuals suffering from diabetes mellitus and gastroparesis, as well as a method for alleviating problems in gastric emptying.

IPC Classes  ?

• A61K 38/11 - Oxytocins; Vasopressins; Related peptides
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

Abstract

The present invention relates to the use of pyruvate dehydrogenase kinase inhibitors at the manufacture of therapeutic agents for treating type 2 diabetes.in mammals.

IPC Classes  ?

• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The present invention relates to a pheromone composition for attracting male Hessian fly, Mayetiola destructor (Say), for monitoring and/or combating purpose, said composition consisting of (2S, 10E)-I O-tridecen-2-yl acetate (2S-E10-13:OAc), (2S)-tridecan-2-yl acetate (2S-13:OAc), (2S,10E)-10-tridecen-2-ol (2S-E10-13OH), and optionally (2S,8E,10E)-8, 10- tridecadien-2-yl acetate (2S-E8-E10-13:OAc) and/or (2S,8Z,10E)-8, 10-tridecadien-2-yl acetate (2S-Z8-E10-13:OAc), as well as a method for attracting said Hessian fly using such a composition.

IPC Classes  ?

• A01N 37/06 - Unsaturated carboxylic acids or thio-analogues thereofDerivatives thereof
• A01N 37/02 - Saturated carboxylic acids or thio-analogues thereofDerivatives thereof
• A01P 19/00 - Pest attractants

Abstract

The present invention relates to a method for diagnosing a risk of acute myocardial infarction, whereby the presence of a polymorphism in the ATP receptor P2Yn is determined, a method for reducing the risk of acute myocardial infarction, an active drug for this purpose, as well as a kit for diagnosing risk of acute myocardial infarction comprising a marker for polymorphism in the ATP receptor P2Y11. The Thr-87 polymorphism is shown to be of particular interest.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention relates to an implantable, disposable barrier disc to be used in negative pressure treatment of wounds, in particular sternotomy wounds, wherein the barrier disc consists of a rigid material withstanding a negative pressure of at least -50 mmHg without causing deformation to the barrier disc, and that the barrier disc is perforated to allow drainage of wound fluid through said barrier disc.

IPC Classes  ?

• A61B 17/00 - Surgical instruments, devices or methods
• A61F 13/14 - Bandages or dressingsAbsorbent pads specially adapted for the breast or abdomen
• A61M 27/00 - Drainage appliances for wounds, or the like

Abstract

The present invention relates to a method for replacing a sterilizing agent in gaseous form with an inert gaseous material in a package to be aseptically or sterile filled, wherein the inert gaseous material is selected in such a way that it has a temperature at addition which provides a volume, which is smaller than the volume of sterilizing agent to replace at the temperature at which the sterilization takes place.

IPC Classes  ?

• B65B 55/10 - Sterilising wrappers or receptacles prior to, or during, packaging by liquids or gases

Abstract

The present invention relates to reaction complex wherein the complex is a Maillard reaction product between a protein selected from the group consisting of soy protein, cereal protein, potato protein, hydrolysed casein and starch, which complex is substantially neutral in taste.

IPC Classes  ?

• A23C 11/08 - Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins containing caseinates but no other milk proteins nor milk fats
• A23C 11/06 - Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins containing non-milk proteins
• A23J 3/10 - Casein
• A23J 3/14 - Vegetable proteins
• A23J 3/16 - Vegetable proteins from soybean
• A23J 3/18 - Vegetable proteins from wheat

Abstract

The present invention relates to a diagnostic method for diagnosing the possible recurrence of breast cancer, wherein the presence of the monoclonal antibody CA- 125 is monitored in a BRCA2 tumour sample, whereby any presence of CA- 125 is indicative of metastazing BRCA2. The invention also relates to the use of monoclonal antibody CA-125, or monoclonal antibody oregovo monoclonal antibody in the preparation of a therapeutic composition for the treatment of breast cancer of the BRCA2 type.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents

Abstract

Loss of Wnt-5a protein expression in breast carcinoma patients is associated with a shorter recurrence-free survival as well as increased motility in mammary cell lines. Based on sequence analysis of Wnt-5a 13 peptide fragments were identified and investigated for their ability to mimic the effects of the Wnt-5a protein on mammary cell adhesion and motility. Two of these peptides significantly increased adhesion and impaired the motility of non-tumourigenic breast cancer cell lines, both low in endogenous Wnt-5a protein expression. To identify the shortest possible peptide that still had an anti-motile effect, sequential deletions of two amino acids from the N-terminal side of the shorter of these two peptides were performed. The effect on tumour cell adhesion was gradually lost, and when only 6 amino acids remained the effect was not detectable. However, formylation of the N-terminal methionine of this hexapeptide restored its effect on adhesion and reduced tumour cell motility. The novel formyl-Met-Asp-Gly-Cys-Glu-Leu peptide ligand can serve as a lead substance for anti-metastatic treatment in the 鲣50% of human breast cancers where the endogenous expression of Wnt-5a is reduced.

IPC Classes  ?

• C07K 14/475 - Growth factorsGrowth regulators
• A61K 38/18 - Growth factorsGrowth regulators
• A61P 35/04 - Antineoplastic agents specific for metastasis

Abstract

The present invention relates to a method for the manufacture of ethanol by fermenting a cellulose containing biomass using a strain of Saccharomyces cerevisiae, wherein the method encompasses a) using a strain of Saccharomyces cerevisiae being capable of fermenting pentoses, including xylose, to ethanol, b) subjecting a slurry of biomass and said Saccharomyces cerevisiae strain for a simultaneous saccharification and co-fermentation of glucose and xylose, and c) isolating ethanol from the fermented slurry obtained.

IPC Classes  ?

• C12P 7/08 - Ethanol, i.e. non-beverage produced as by-product or from waste or cellulosic material substrate
• C12R 1/865 - Saccharomyces cerevisiae

Abstract

A thermostable, alkaline active xylanase was purified from an alkaliphilic Bacillus halodurans S7, isolated from a soda lake in the Ethiopian Rift Valley. The molecular weight and the pi of this enzyme were around 43 kDa and 4.5, respectively. The optimum temperature for the activity was 75 °C at pH 9 and 70 °C at pH 10. The enzyme was stable over a broad pH range and showed good thermal stability when incubated at 65 °C in pH 9 buffer. The enzyme activity was strongly inhibited by Mn2+ with partial inhibition in the presence of 5 mM Cu2+, Co2+ and EDTA. Inhibition by Hg2+ and dithiothreitol was insignificant. The enzyme was free from cellulase activity. The properties of the xylanase produced by this organism are very attractive for use in pulp treatment and recycling, detergent formulation, feed applications, separation of starch and gluten and waste management.

IPC Classes  ?

• C12N 9/42 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4-glucosidic bonds, e.g. cellulase
• A21D 8/04 - Methods for preparing doughTreating dough prior to baking treating dough with microorganisms or enzymes
• C11D 3/386 - Preparations containing enzymes
• C12N 1/20 - BacteriaCulture media therefor
• D21C 3/00 - Pulping cellulose-containing materials
• C12R 1/07 - Bacillus